Gregg M. Gellman Appointed CEO of Open Implants: Offers Deep Medical Device Development & Manufacturing Business Development Experience

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

February 3, 2021

Gregg M. Gellman has more than 15 years of experience, leading and growing biomedical companies. He brings a unique and strong skill set to the company.

Gellman’s previous experience includes executive leadership roles at EBI Biomet, now Zimmer Biomet, Greatbatch now Integer Holdings, EnerMed now Garwood Medical, StimMed and Thinking Robot Studios where he will continue to serve as a Board Member for both companies. He has a proven track record in product development, commercialization of regulated applications/products, regulatory and sales. Gellman is a graduate of the State University of New York at Buffalo. He is certified in Quality Systems for Medical Devices (FDA’s QSR and ISO 13485) and in Global Product Submissions Directive Requirements (510(k), PMA, CE Mark).

Greg M. Gellman feels this is a tremendous opportunity to contribute to building on what Open Implants has already accomplished. “My roots are in orthopedics, regulated manufacturing and advanced technologies and I look forward to working with customers and the Open Implants team to accelerate product development and increase our commitments to insure customer satisfaction and above all positive clinical outcomes for patients who require dental surgery.”

Rob Nazzal, Co-founder and Board Member, says, “Gregg’s deep experience in medical device development, manufacturing, and business development, will be an enormous asset for Open Implants. With Gregg onboard, we are accelerating our roadmap to deliver more comprehensive solutions to the evolving digital dentistry world. We are privileged to have Gregg on our team.”

Gregg M. Gellmen succeeds Frederic Rapp, who is also a co-founder of Open Implants. Rapp will continue as a member of the Board of Directors and will also continue full-time leadership of his dental laboratory, CrownCeram, in France.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.